StoneRidge PMG Advisors, LLC’s Opus Genetics IRD Stock Holding History

StoneRidge PMG Advisors, LLC’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$61K	Buy	+12,695	New	+$52.7K	0.04%	145

Other funds holding IRD

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return

James Investment Research Alpha, Ohio $936M AUM 24.49% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.25% 1-Year Est. Return

Sanders Morris Harris Houston, Texas $755M AUM 11.28% 1-Year Est. Return

First City Capital Management Savannah, Georgia $204M AUM 20.28% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

StoneRidge PMG Advisors, LLC's IRD Position: Q3 2026 in Review

StoneRidge PMG Advisors, LLC opened a new position in Opus Genetics (IRD) in Q3 2026: 12,695 shares worth $61K. The stake represents 0.04% of the portfolio and ranks #145 among its holdings.

23 funds tracked by Wall St. Rank hold IRD as of Q3 2026.

StoneRidge PMG Advisors, LLC held 12,695 shares of Opus Genetics worth $61K as of Q3 2026.
Opus Genetics was a new StoneRidge PMG Advisors, LLC position in Q3 2026.
Opus Genetics made up 0.04% of StoneRidge PMG Advisors, LLC's portfolio in Q3 2026, its #145 holding.
23 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2026.

Based on StoneRidge PMG Advisors, LLC's 13F filing for Q3 2026, filed 4 Nov 2026.